PEG-MGF
PEGylated Mechano Growth Factor
PEG-MGF (PEGylated Mechano Growth Factor) is a modified version of the MGF splice variant of IGF-1 with polyethylene glycol chains attached to extend its biological half-life from minutes to several hours. This PEGylation converts MGF from a locally-acting autocrine factor into a systemically bioavailable peptide capable of reaching muscle tissue through the circulation. It is a research compound studied for enhanced muscle repair, recovery, and growth signaling with more practical dosing compared to unmodified MGF.
Mecanismo de Acción
PEGylated version of mechano growth factor with polyethylene glycol chains attached to extend half-life. Preserves satellite cell activation and muscle repair properties of MGF while allowing systemic rather than purely local administration.
Protocolos de Investigación
Para propósitos de investigación solo. No es asesoramiento médico.
Research protocols use 200-400mcg 2-3 times per week via intramuscular injection into target muscle groups. Can be rotated across muscle groups. Cycles of 4-8 weeks.
Notas de Investigación
Clinical Research Status
PEG-MGF has not entered formal clinical trials and remains a research-grade compound without regulatory status. Its development represents a pharmacokinetic optimization of the naturally-occurring MGF splice variant to address the impractically short half-life of the native peptide. Academic interest focuses on whether systemic delivery of PEGylated MGF can replicate the local satellite cell activation observed with natural MGF expression after exercise.
Key Published Findings
Animal studies suggest PEGylated MGF administered systemically can reach muscle tissue and promote satellite cell activation, though at lower local concentrations than achieved through direct intramuscular injection of native MGF. The PEGylation extends circulating half-life from approximately 5-7 minutes to several hours, allowing subcutaneous administration with meaningful systemic exposure. Research indicates the PEG moiety does not significantly impair receptor binding of the E-domain peptide.
Safety Profile
No human safety data exists for PEG-MGF, and risk assessment relies entirely on extrapolation from in vitro and animal studies. PEGylated compounds carry general risks of PEG-associated immune responses (anti-PEG antibodies) with repeated dosing, potentially reducing efficacy over time. The systemic nature of PEG-MGF raises broader safety considerations than local MGF, as satellite cell activation in non-target tissues (including cardiac muscle) could potentially occur.
Comparison to Related Compounds
Compared to unmodified MGF, PEG-MGF offers practical subcutaneous dosing but loses the tissue-specific local action that characterizes natural MGF biology. Unlike IGF-1 LR3 which activates the full IGF-1 receptor signaling cascade, PEG-MGF theoretically targets the earlier satellite cell activation phase rather than direct protein synthesis stimulation. The PEGylation approach mirrors pharmaceutical strategies used for other peptides (PEG-filgrastim, PEG-interferon) to reduce dosing frequency.
Community Observations
Protocols typically use PEG-MGF at 200-400 mcg administered subcutaneously on training days, based on empirical use rather than pharmacokinetic optimization. Some researchers question whether the PEGylated form adequately replicates the natural autocrine signaling pattern or whether systemic delivery fundamentally changes the biological response. The compound is often used in combination with IGF-1 LR3, with PEG-MGF theorized to expand satellite cell populations that IGF-1 LR3 then drives toward differentiation and hypertrophy.
Media Vida
~Several days
Reconstitución
Bacteriostatic water (BAC)
Almacenamiento
Liofilizado
Refrigerate 2-8C up to 18 months.
Reconstituído
Refrigerate 2-8C. Use within 14 days.
Estado Legal EE.UU.
También Se Conoce Como
Preguntas frecuentes
¿Qué es PEG-MGF?
PEG-MGF (PEGylated Mechano Growth Factor) is a modified version of the MGF splice variant of IGF-1 with polyethylene glycol chains attached to extend its biological half-life from minutes to several hours. This PEGylation converts MGF from a locally-acting autocrine factor into a systemically bioavailable peptide capable of reaching muscle tissue through the circulation. It is a research compound studied for enhanced muscle repair, recovery, and growth signaling with more practical dosing compared to unmodified MGF.
¿Cómo funciona PEG-MGF?
PEGylated version of mechano growth factor with polyethylene glycol chains attached to extend half-life. Preserves satellite cell activation and muscle repair properties of MGF while allowing systemic rather than purely local administration.
¿Cuál es el estado regulatorio de PEG-MGF en EE. UU.?
Research chemical (not FDA-approved)
¿Cuál es la vida media de PEG-MGF?
~Several days
¿Qué otros nombres tiene PEG-MGF?
PEGylated Mechano Growth Factor
Peptide Contacts proporciona resúmenes basados en investigaciones únicamente para fines informativos. No hospedamos, distribuimos ni endosamos la documentación del proveedor. Todos los certificados de análisis, certificados GMP y comunicaciones del proveedor deben solicitarse y verificar directamente por el comprador. Nada en esta plataforma constituye asesoramiento legal, médico o profesional. Los usuarios son únicamente responsables de verificar las credenciales del proveedor y asegurarse de cumplir con todas las leyes locales, estatales y federales aplicables antes de comprar cualquier químico de investigación. El uso de esta plataforma constituye aceptación de toda la responsabilidad personal.
Leer aviso completo